| Literature DB >> 22713677 |
James K Ellis1, Toby J Athersuch, Laura D K Thomas, Friederike Teichert, Miriam Pérez-Trujillo, Claus Svendsen, David J Spurgeon, Rajinder Singh, Lars Järup, Jacob G Bundy, Hector C Keun.
Abstract
BACKGROUND: The 'exposome' represents the accumulation of all environmental exposures across a lifetime. Top-down strategies are required to assess something this comprehensive, and could transform our understanding of how environmental factors affect human health. Metabolic profiling (metabonomics/metabolomics) defines an individual's metabolic phenotype, which is influenced by genotype, diet, lifestyle, health and xenobiotic exposure, and could also reveal intermediate biomarkers for disease risk that reflect adaptive response to exposure. We investigated changes in metabolism in volunteers living near a point source of environmental pollution: a closed zinc smelter with associated elevated levels of environmental cadmium.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22713677 PMCID: PMC3391181 DOI: 10.1186/1741-7015-10-61
Source DB: PubMed Journal: BMC Med ISSN: 1741-7015 Impact factor: 8.775
Figure 1Metabolic profiling in molecular epidemiology: a methodology to identify intermediate biomarkers of response to environmental toxicants. A) Map of United Kingdom showing Bristol region. Reproduced from Ordnance Survey map data by permission of the Ordnance Survey © Crown copyright 2010. B) Air Cd concentration around the Avonmouth zinc smelter site (data from Thomas et al. (2009)[37]). Contours represent modeled air Cd concentration (ng/m3). Dotted line represents boundary of Bristol North PCT from where volunteers were recruited. C) Partial 1H NMR one dimensional spectrum with key metabolites annotated. 3-HV, 3-hydroxyisovalerate; DMG, dimethylglycine. D) Outline of the metabolic profiling and statistical methods used to define associations between the metabolome and environmental toxicants.
Statistics of multivariate analysis models demonstrating an association between 1H NMR spectroscopic data and several biological and lifestyle factors.
| Model Description | Y variable | Number of LVs | R2X | Q2Y | Significance |
|---|---|---|---|---|---|
| ln(U-Cd) | 3 | 0.251 | 0.237 | < 0.01 | |
| ln(U-Cd) | 5 | 0.308 | 0.330 | < 0.001 | |
| ln(U-Cd) | 1 | 0.0729 | 0.142 | < 0.001 | |
| sex | 3 | 0.241 | 0.104 | > 0.05 | |
| age | 2 | 0.216 | 0.224 | < 0.001 | |
| ln(U-NAG) | 1 | 0.054 | 0.162 | < 0.001 | |
| Smoking historya | 2 | 0.194 | 0.185 | < 0.01 |
aSmoking history was defined as either 1 = never smoked and past smoker (n = 106) or 2 = current smoker (n = 20), one individual did not complete the lifestyle questionnaire. Spectra that exhibited signs of bacterial contamination, analgesics or ethanol were excluded from these analyses. All variables were mean-centred and scaled to unit variance. NMR data were reduced to 1,127 data points of δ 0.01 resolution. Sample numbers for PLS models: A, D, E and F: n = 127. B: n = 106. C: n = 79. PLS-DA (model G) n = 126. Number of latent variables in a model were auto-fitted in SIMCA-P+. All models were assessed for validity by Y variable permutation analysis (1,000 permutations, see additional file 1 Figure S4). Scores scatter plots for each multivariate model can also be found in additional file 1 (Figure S5). ln(U-Cd), natural logarithm of urinary cadmium; ln(U-NAG), natural logarithm of urinary-N-acetyl-β-D-glucosaminidase; LV, latent variable; n, sample number; PLS, partial least squares; PLS-DA, partial least squares - discriminant analysis. R2X is the proportion of variance in the X matrix (i.e. spectral NMR data) described by the PLS model. Q2Y is the ability of the PLS model to predict the Y-score (ln(U-Cd), sex, age, ln(U-NAG) or smoking status) of a novel sample or the "cross-validated goodness-of-fit".
Figure 2Covariance and correlation between . The color code (R2) corresponds to the correlation coefficients of the variables with each of the characteristics: A, ln(U-Cd); B, age; C, sex; D, ln(U-NAG); and E, smoking status. N = 127. α - The direction and magnitude of the signals relate to the covariation of the metabolites with sex in the model, that is, female (positive) and male (negative). β - Smoking status was classified into two classes. 1 = never smoked (negative), 2 = current smoker (positive). 3-HV, 3-hydroxyisovalerate; DMG, dimethylglycine; 4-DEA, 4-deoxyerythronic acid. Spectra that exhibited signs of bacterial contamination, analgesics or ethanol were excluded from these analyses [See additional file 1 Table S2].
Correlation coefficients (standardized beta values) derived from multiple linear regression of key metabolite to lifestyle factors.
| Metabolite | Chemical shift | Sample number | Correlation to Y variable | |||
|---|---|---|---|---|---|---|
| 3-HV | 1.276 to 1.269 | 160 | -0.056 | -0.023 | ||
| DMG | 2.936 to 2.920 | 176 | -0.127 | -0.122 | -0.168 | -0.052 |
| citrate (1) | 2.515 to 2.590 | 175 | -0.078 | 0.126 | ||
| citrate (2) | 2.515 to 2.590 | 143 | -0.060 | 0.157 | ||
| citrate (3) | 2.515 to 2.590 | 108 | -0.046 | 0.121 | n/a | |
| Creatinine | 4.073 to 4.040 | 178 | -0.010 | 0.015 | ||
| Creatine | 3.940 to 3.930 | 178 | -0.006 | 0.088 | 0.150 | |
| 4-DEA | 1.118 to 1.108 | 152 | -0.042 | -0.076 | 0.039 | |
aSmoking status was classified into three classes. 1 = never smoked, 2 = past smoker and 3 = current smoker. Specific exclusions were made for each metabolite identified where coinciding interferences made the relevant resonance unsuitable for integration. All six metabolites were correlated to at least one of the epidemiological factors in either the PLS/PLS-DA regression analysis or the covariance/correlation models. Asterisks denote statistical significance (ANOVA with Bonferroni post-hoc correction): * P < 0.05, ** P < 0.01, *** P < 0.001. U-Cd was log normally distributed.
citrate (1) all three classes included (never smoked, past- and current-smoker). Note, three samples excluded. citrate (2) current-smokers additionally excluded. citrate (3) past- and current-smokers additionally excluded. ANOVA, analysis of variance; 3-HV, 3-hydroxyisovalerate; DMG, dimethylglycine; 4-DEA, 4-deoxyerythronic acid; PLS, partial least squares; PLS-DA, partial least squares - discriminant analysis; U-Cd, urinary cadmium.
Figure 3The association between (A) relative citrate concentration and smoking status, and (B) U-Cd and U-8-oxodG. (A) Normalized citrate levels in never, past and current smokers. ** statistically significant difference to 'never smoked' group, P < 0.01 (Kruskal-Wallis with Mann-Whitney post-test). Correlation coefficient (citrate versus smoking status), ρ = -0.225, P = 0.002 (Spearman's rho). Never smoked n = 108, past smoker n = 35, current smoker n = 32. (B) * statistically significant difference, P < 0.05 (Mann-Whitney test). N = 40, 20 per group. Median values marked with 95% confidence intervals represented as error bars. Data points falling outside these confidence intervals are marked.